ATG versus OKT3 in the treatment of steroid-resistant rejection following living-related donor renal transplantation.
Uslu
A
A
Ege University Organ Transplantation and Research Center, Ege University Medical School, Bornova/Izmir, Turkey.
Tokat
Y
Y
Ok
E
E
Unsal
A
A
Ilkgul
O
O
Kaplan
H
H
D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005190:Family; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000628:therapy*; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D019520:Living Donors; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use*; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D012189:Retrospective Studies; D015996:Survival Rate
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D003404:Creatinine; D008775:Methylprednisolone